Skip navigation

Tracking Emerging State Price Transparency, Reporting and Disclosure Laws to Ensure Compliance

March 26, 2019
  • Philadelphia, PA

State drug pricing regulations remain in the headlines as state legislatures across the nation continue to introduce and pass laws aimed at transparency and reporting obligations leaving many unanswered questions and a myriad of legislative and compliance complexities. Are you prepared for the impact on drug pricing and compliance practices?

CBI’s 4th Edition Drug Pricing Transparency Congress features sessions including:

  • Review drug pricing transparency legislative and litigation
    developments — including a deep dive state-by-state analysis
    of laws in Oregon, California, Nevada, Connecticut, New York
    and Vermont
  • Explore how the future of drug pricing transparency regulation
    will impact commercialization, reimbursement and
    drug pricing models
  • Deliver comprehensive legal interpretations of drug pricing
    transparency and reporting laws currently on the books and
    the policy outlook for 2019
  • Benchmark overall state compliance practices related to
    drug pricing reporting
  • Discuss organizational shifts within legal and compliance
    departments to handle drug pricing obligations and reporting

Don’t miss this timely event — register today!

4th Edition Drug Pricing Transparency Congress

Tracking Emerging State Price Transparency, Reporting and Disclosure Laws to Ensure Compliance

State drug pricing regulations remain in the headlines as state legislatures across the nation continue to introduce and pass laws aimed at transparency and reporting obligations leaving many unanswered questions and a myriad of legislative and compliance complexities. Are you prepared for the impact on drug pricing and compliance practices?

CBI’s 4th Edition Drug Pricing Transparency Congress features sessions including:

  • Review drug pricing transparency legislative and litigation
    developments — including a deep dive state-by-state analysis
    of laws in Oregon, California, Nevada, Connecticut, New York
    and Vermont
  • Explore how the future of drug pricing transparency regulation
    will impact commercialization, reimbursement and
    drug pricing models
  • Deliver comprehensive legal interpretations of drug pricing
    transparency and reporting laws currently on the books and
    the policy outlook for 2019
  • Benchmark overall state compliance practices related to
    drug pricing reporting
  • Discuss organizational shifts within legal and compliance
    departments to handle drug pricing obligations and reporting

Don’t miss this timely event — register today!